All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
about
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptidesTreatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceSofosbuvir.Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Direct-acting antivirals for chronic hepatitis C.Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.Development of sofosbuvir for the treatment of hepatitis C virus infection.New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes.Direct-acting antivirals for chronic hepatitis C
P2860
Q24564462-BB635DAB-2135-4610-94D2-46CB2CB41C15Q26740219-EFD8E4AB-D493-4B1C-8099-9D8B591A1B39Q33774724-532B61B1-CFB4-4092-B5F5-8DDD19AE39C4Q34420891-7F7CCA3A-6A03-4C24-BF88-299C828A82D4Q34557595-195266DB-8CE2-464B-9B82-19999E842A93Q35818327-D9AD7A33-191B-4756-9078-C4DE0E9CFE78Q36290604-499E9693-831C-447C-BBAB-AD0AF3040B16Q38164242-E4C7FF1F-9BC0-452C-9E4B-E69CD57D0AF1Q38559442-7455F088-259D-4B64-B077-41B52E5F4235Q38664453-0647765D-2ECE-4DF6-9057-70158A7E5448Q38995024-83AA5BCC-778E-4700-92DB-F7DFF2B7AD33Q39301797-FA7CD88C-0A94-443D-AAF4-7E155F95C100Q40480795-68C29E38-EC59-4808-AB8D-0C2AB913873EQ57389418-3CF93966-F422-4CC4-AC14-3303B2E5A19C
P2860
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
All-oral therapy with nucleoti ...... otype 1 hepatitis C (nuclear).
@en
All-oral therapy with nucleoti ...... t-naive genotype 1 hepatitis C
@nl
type
label
All-oral therapy with nucleoti ...... otype 1 hepatitis C (nuclear).
@en
All-oral therapy with nucleoti ...... t-naive genotype 1 hepatitis C
@nl
prefLabel
All-oral therapy with nucleoti ...... otype 1 hepatitis C (nuclear).
@en
All-oral therapy with nucleoti ...... t-naive genotype 1 hepatitis C
@nl
P2093
P2860
P356
P1476
All-oral therapy with nucleoti ...... otype 1 hepatitis C (nuclear).
@en
P2093
E J Lawitz
M M Berrey
M Rodriguez-Torres
M T Cornpropst
W T Symonds
P2860
P304
P356
10.1111/JVH.12091
P577
2013-03-31T00:00:00Z